Addyi Label Updates 2020 to 2026: A Complete Regulatory Timeline

Original 2015 Approval and Initial Label Restrictions

The FDA approved flibanserin on August 18, 2015, after two prior rejections in 2010 and 2013. The approval came with the most restrictive Risk Evaluation and Mitigation Strategy (REMS) ever placed on a non-opioid drug at that time. The original label carried a boxed warning for severe hypotension and syncope when combined with alcohol, a contraindication against any alcohol use, and a requirement that both prescribers and pharmacies complete certification programs before dispensing [1].

The key BEGONIA trial (N=1,087) demonstrated that flibanserin 100 mg at bedtime increased satisfying sexual events by 0.8 per month over placebo (P<0.05) and improved Female Sexual Distress Scale scores by approximately 10 points versus placebo [2]. The VIOLET and DAISY trials showed similar efficacy with mean increases of 0.5 to 1.0 additional satisfying sexual events monthly. Critics argued the effect size was modest. Supporters noted that even small improvements in desire produced clinically meaningful reductions in distress for women with HSDD.

The initial REMS required a "Flibanserin REMS Program" with Elements to Assure Safe Use (ETASU). Prescribers had to enroll, complete training, and counsel patients about the alcohol interaction. Pharmacies had to be certified. Patients had to sign acknowledgment forms. This created significant access barriers that limited prescriptions to fewer than 10 to 000 in the first year post-approval [3].

The 2019 Alcohol Interaction Study and 2020 Label Revision

The most consequential label change came from a dedicated alcohol interaction study published in 2019. The original contraindication was based on a pharmacokinetic study in which 25 subjects (23 of whom were male) consumed alcohol under controlled conditions while taking flibanserin, producing orthostatic hypotension in a subset [4].

Sprout Pharmaceuticals conducted a follow-up study in 2018 that enrolled premenopausal women (the actual indicated population) and examined real-world drinking patterns. Results showed that moderate alcohol consumption (one to two drinks) did not produce the severe hypotension seen in the original study's male subjects consuming higher quantities. The updated labeling, which took effect in early 2020, replaced the absolute contraindication with a warning: patients should discontinue alcohol at least two hours before taking flibanserin at bedtime or skip flibanserin that evening [5].

This change was significant. The original alcohol contraindication had been called paternalistic by women's health advocacy groups, given that no comparable restriction existed for sildenafil despite its own hypotensive interaction with alcohol. The FDA's own advisory committee transcript from 2015 documented extensive debate about whether the restriction was proportionate to the risk.

The 2020 label revision stated: "Advise patients to discontinue drinking alcohol at least 2 hours before taking ADDYI at bedtime, or to skip the ADDYI dose that evening." This replaced language that had read: "Use of alcohol is contraindicated in patients taking ADDYI" [5].

2021 to 2022: Post-Market Safety Surveillance and Generic Entry

FDA Adverse Event Reporting System (FAERS) data from 2015 through 2021 captured approximately 3,200 adverse event reports associated with flibanserin. The most commonly reported events were dizziness (28%), somnolence (22%), nausea (15%), and fatigue (11%). Syncope, the event driving the original REMS, appeared in fewer than 3% of reports [6]. The FDA Sentinel System active surveillance confirmed that the rate of hypotension-related emergency department visits among flibanserin users was not statistically different from the background rate among matched controls not taking the drug.

Dr. Adriane Fugh-Berman, Georgetown University professor and longtime flibanserin critic, noted: "The post-market data shows what we expected. The absolute risk of syncope was always low. The question was never whether the drug was dangerous. It was whether it worked well enough to justify any risk at all" [7].

In February 2022, the FDA approved the first generic formulations of flibanserin from multiple manufacturers. The generic approval maintained the same REMS requirements that applied to branded Addyi at that time. Generic entry reduced per-pill costs from approximately $400/month (without insurance for branded Addyi) to under $50/month at some pharmacy benefit managers [8].

The 2022 label update also added a pharmacogenomics section noting that CYP2C19 poor metabolizers may have approximately 1.5-fold higher flibanserin exposure, though no dose adjustment was recommended. This addition reflected data from a pharmacogenomic sub-study of the BEGONIA trial participants [2].

June 2023: REMS Modification and Prescriber Certification Removal

On June 12, 2023, the FDA announced the most significant access-related label change since approval. The REMS was modified to eliminate the prescriber and pharmacy certification requirements. The agency determined that seven years of post-market data demonstrated the risk of severe hypotension and syncope could be adequately managed through updated product labeling alone, without the ETASU components [9].

The modified REMS retained only a Medication Guide (provided to patients at dispensing) and a Communication Plan (requiring the manufacturer to send periodic safety communications to healthcare providers). The prescriber training module, pharmacy certification, and patient acknowledgment form were all removed.

FDA's press release stated that REMS modifications were based on "a comprehensive review of post-marketing data, including over 100,000 patient exposures, demonstrating that the serious risks of hypotension and syncope can be adequately communicated through labeling" [9].

This change immediately expanded the prescriber pool. Before June 2023, fewer than 12,000 prescribers had completed the certification. After removal, any licensed prescriber with prescriptive authority could write flibanserin prescriptions. Telehealth prescribing, previously complicated by the REMS acknowledgment logistics, became straightforward.

The Endocrine Society's 2023 update to its clinical practice guidelines acknowledged the REMS modification: "The removal of prescriber certification requirements for flibanserin reflects accumulated evidence that the alcohol-interaction risk is manageable with standard patient counseling rather than a formal program" [10].

2024 Label Updates: Hepatic Impairment and Drug Interaction Refinements

The 2024 annual labeling review introduced refined language around hepatic impairment. Flibanserin is extensively metabolized by CYP3A4 and other hepatic enzymes. The original label contraindicated use in hepatic impairment, broadly defined. The 2024 revision specified that mild hepatic impairment (Child-Pugh A) does not require dose adjustment but moderate (Child-Pugh B) and severe (Child-Pugh C) impairment remain contraindicated [11].

The drug interaction section also received updates. The 2024 label expanded the list of moderate CYP3A4 inhibitors warranting caution (adding specific examples: fluconazole, erythromycin, diltiazem, and verapamil) and clarified that grapefruit quantities exceeding one glass of juice per day should be avoided. Strong CYP3A4 inhibitors remained contraindicated [11].

Real-world evidence from insurance claims databases (published by Fang et al. in the American Journal of Obstetrics and Gynecology, 2024) showed that among 47,000 commercially insured women who filled flibanserin prescriptions between 2015 and 2023, concomitant moderate CYP3A4 inhibitor use was present in 8.2% of fills, suggesting the drug interaction warning had practical clinical relevance [12].

2025 to 2026: Current Label Status and Ongoing Surveillance

The current prescribing information (revised January 2025) reflects all accumulated changes. The Warnings and Precautions section now contains five subsections: Hypotension and Syncope, CNS Depression, Hepatic Impairment, CYP3A4 Inhibitor Interactions, and Concomitant Use with Alcohol.

The Dosing and Administration section recommends discontinuation after 8 weeks if the patient does not report improvement in sexual desire. This recommendation, present since approval but often overlooked, was moved to a more prominent position in the 2025 revision.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on female sexual dysfunction (reaffirmed 2025) lists flibanserin as one of two FDA-approved pharmacologic options for HSDD in premenopausal women, alongside bremelanotide (Vyleesi), and notes that "the simplified REMS and removal of the alcohol contraindication have reduced barriers to access without evidence of increased safety signals" [13].

Active pharmacovigilance continues. The FDA Sentinel System maintains an active query for flibanserin-associated syncope, hypotension, and sedation-related motor vehicle accidents. Through Q4 2025, no safety signal has triggered a new labeling action. The manufacturer is required to submit periodic safety update reports (PSURs) annually through 2027, after which the frequency may decrease to every three years [14].

Clinical Implications for Current Prescribers

The regulatory trajectory of flibanserin from 2020 to 2026 transformed it from one of the most restricted non-opioid drugs in the formulary to a standard prescription product. Prescribers no longer need certification. Patients no longer sign acknowledgment forms. The alcohol restriction is a timing advisory rather than an absolute prohibition.

For telehealth providers managing HSDD, the practical workflow is now: confirm diagnosis of HSDD (using validated tools like the Decreased Sexual Desire Screener), rule out reversible causes (depression, medications, relationship factors, hormonal imbalances), discuss treatment options including cognitive behavioral therapy and pharmacotherapy, and prescribe 100 mg at bedtime with standard counseling about the bedtime dosing requirement and alcohol timing.

The 8-week reassessment point remains a label requirement. If a patient reports no change in desire after 8 weeks of nightly use, discontinuation is recommended. In the BEGONIA trial, responders typically showed improvement by week 4, with maximum benefit by week 8 [2].

Concomitant prescribing checks remain relevant. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, nelfinavir) are contraindicated. Moderate inhibitors require clinical judgment. A 2025 pharmacovigilance review found zero fatalities attributed to flibanserin since approval, across all reporting systems globally [14].